Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Retained Earnings (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Retained Earnings readings, the most recent being -$642.2 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 142494.9% to -$642.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$642.2 million, a 142494.9% decrease, with the full-year FY2025 number at -$642.2 million, down 142494.9% from a year prior.
  • Retained Earnings hit -$642.2 million in Q4 2025 for Aligos Therapeutics, down from -$622.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $497000.0 in Q2 2023 to a low of -$642.2 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$348.7 million (2022), compared with a mean of -$298.7 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 100.26% in 2021 and later crashed 288716.35% in 2023.
  • Aligos Therapeutics' Retained Earnings stood at $452000.0 in 2021, then decreased by 11.28% to $401000.0 in 2022, then plummeted by 121495.76% to -$486.8 million in 2023, then skyrocketed by 100.09% to $451000.0 in 2024, then plummeted by 142494.9% to -$642.2 million in 2025.
  • The last three reported values for Retained Earnings were -$642.2 million (Q4 2025), -$622.3 million (Q3 2025), and $420000.0 (Q2 2025) per Business Quant data.